The FDA’s new support of a single study approach has drawn much discussion, raising questions as to whether conducting just one confirmatory study is a risky position for sponsors to take. In this blog, Andrew Garrett,...
-
ICON’s acquisition of Symphony Clinical Research
The acquisition further enhances ICON’s patient, site and data strategy and complements ICON’s existing PMG Research and MeDiNova Research site networks in the US and EMEA.
-
ICON announces the appointment of Ms. Julie O’Neill to Board of Directors
And confirms the retirement of Professor Dermot Kelleher and Mr. Declan McKeon
-
Forbes names ICON in list of Best Employers in America for Women
ICON recognised as top employer for women in anonymous survey of 60,000 employees.
-
ICON’s acquisition of MeDiNova research
The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.
-
ICON awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research
ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards.
-
ICON launches new patient engagement platform to support improved patient experience & enrolment in clinical trials
Increasing visibility of potential study participants to sites and sponsors.
-
Forbes names ICON one of the best employers in America
ICON ranked top CRO in anonymous survey of 50,000 employees across 38 sectors
-
ICON wins multiple categories in 2019 CRO Leadership Awards
ICON recognised for specialised services offering across product development lifecycle.
-
ICON acquires MolecularMD
ICON enhances it molecular diagnostic testing services, a key area in oncology research, with it's acquisition of MolecularMD.
-
ICON launches new drug safety reporting solution ensuring compliance through automation
Developed on platform deploying rule-based automation for timely delivery of drug safety information.
